【dslr with most megapixels】Memgen Announces Addition to Board of Directors
HOUSTON / ACCESSWIRE / April 2,dslr with most megapixels 2020 /
Memgen, a private biotechnology company developing innovative immuno-oncology drugs, announced today that Christopher Pagano has joined the company's Board of Directors.
"I am delighted to join the board of Memgen at this exciting time in the company's development," noted Mr. Pagano. "Memgen is exploiting leading-edge science to develop novel and effective treatments for cancer patients who currently face limited options, and it is gratifying to be able to contribute to moving these products closer to becoming a therapeutic reality."
Dr. Robert Coates, Memgen's Executive Chairman, stated, "We are pleased to be able to attract a professional of Chris's caliber to Memgen, and welcome him to the board. Chris brings his extraordinary experience as a C-Suite financial executive at a Fortune 500 company to Memgen as well his intense interest in biotechnology. We look forward to working closely with him."
Dr. Gregory Brown, Memgen's CEO, also noted, "We are thrilled that Chris has joined the Memgen team, further enriching the leadership capabilities necessary to achieve our mission of delivering novel and effective cancer therapies through the clinic and to patients."
Mr. Pagano has enjoyed a long and successful career, culminating in C-level positions with Assurant, Inc. a NYSE-traded insurance company, where he served successively as Chief Investment Officer, Chief Financial Officer, and Chief Risk Officer over twenty-three years. Previously he served as Portfolio Manager and Head of Fixed Income Asset Management at Assurance Asset Management and became its President and CIO shortly after the company's successful IPO in 2004. He has an MBA from the University of Chicago Graduate School of Business, a BS in Economics from the University of Pennsylvania Wharton School, and has earned the Chartered Financial Analyst (CFA) designation.
About Memgen
Memgen is a cancer immunotherapy company focused on creating drugs that harness the power of the immune system to cure cancer. Its first-in-class immune-oncology therapeutics are designed for the treatment of patients who do not respond to currently available therapeutic options. The Company's lead product, MEM-288, is engineered to both selectively target cancer cells and supercharge the immune system through expression of two unique and powerful immune modulators: CD40 ligand (CD40L) and the powerful cytokine interferon beta. MEM-288 has been demonstrated to generate a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. The Company expects to begin clinical testing with MEM-288 in the current year. The Company's pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already been tested in human subjects and has demonstrated the ability to elicit powerful, antigen-specific anti-tumor immune responses across a broad range of tumor types.
Story continues
In this press release, unless the context requires otherwise, "Memgen", the "Company," "Companies," "we," "our," and "us" refers to Memgen, LLC.
Investor Contact:
Gregory B. Brown, M.D.
(203) 940-3742
Media Contacts:
Gregory B. Brown, M.D.
(203) 940-3742
Related Images
SOURCE:
Memgen
View source version on accesswire.com:
https://www.accesswire.com/583459/Memgen-Announces-Addition-to-Board-of-Directors
View comments
(责任编辑:Encyclopedia)
- EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
- Maybe the Coronavirus Didn’t End the Bull Market
- EXCLUSIVE: Frédéric Arnault Gears Up for CEO Role at Tag Heuer
- Berkshire Hathaway annual meeting 2020: 5 things to know
- The Bar Harbor Bankshares (NYSEMKT:BHB) Share Price Is Down 38% So Some Shareholders Are Getting Worried
- Is The L.S. Starrett Company (SCX) Going to Burn These Hedge Funds?
- SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Canaan Inc. and Encourages Investors with Losses to Contact the Firm
- Daseke Sees Flatbed Softness Continuing Through First Half Of 2020
- Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal
- Fiat Chrysler postpones shareholders' meeting and resolution on dividend to late June
- 20 Ways To Earn Extra Money Before Black Friday
- GBP/USD Price Forecast – British Pound Continues to Struggle at Same Level
- Nio Deliveries Jump 109% In November, Boosts Production Capacity To Keep Pace With Rising Demand
- Domino's (DPZ) Opens 17,000th Store, Expands in Australia
- NEWSMAKER-So near yet so far for Malaysia's Anwar
- FTC Sending More Than $470K to People Duped by My7Network, ‘Bitcoin Funding Team’ Scams
- CanWel Building Materials Group (TSE:CWX) Shareholders Have Felt Some Pain With A 19% Loss On Their Investment
- When Can We Expect A Profit From Asmallworld AG (VTX:ASWN)?
- Patrick Downey Is The President of Orezone Gold Corporation (CVE:ORE) And They Just Spent US$108k On Shares
- How Much is Wisdom Education International Holdings Company Limited's (HKG:6068) CEO Getting Paid?